Abstract
• This paper reports on the significance of determining patient worsening rates in double-blind crossover clinical trials. It is felt that the determination of the worsening rate in clinical trials of psychotropic agents is an additional dimension for determining the efficacy of the test agent. This report contains analyses and discussions of 34 double-blind crossover studies, where a psychotropic agent, Nobrium, was compared to placebo in 27 studies and to phenobarbital in 7 studies. METHOD
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
